Eli Lilly acquires Kelonia Therapeutics for $3.25 billion to boost oncology pipeline
Eli Lilly announced the acquisition of Kelonia Therapeutics for $3.25 billion upfront, marking a strategic expansion beyond its blockbuster GLP-1 drugs into oncology and genetic medicines. The deal, structured as an upfront payment, underscores Lilly's commitment to diversifying its pipeline amid rising competition in the diabetes and weight-loss market. Kelonia, a private biotech firm, specializes in genetic medicine technologies, including novel delivery systems for gene therapies. The acquisition is expected to close in the second quarter of 2025, pending regulatory approvals. This move follows Lilly's recent investments in cancer research, including a $1.6 billion deal for a radiopharmaceutical company in 2024. The transaction highlights the growing interest in genetic medicines as a frontier for treating solid tumors and rare diseases.
Key facts
- Eli Lilly announced acquisition of Kelonia Therapeutics for $3.25 billion upfront.
- The deal is aimed at expanding Lilly's oncology and genetic medicines pipeline.
- Kelonia Therapeutics is a private biotech company focused on genetic medicine technologies.
- The acquisition moves Lilly beyond its GLP-1 drugs (e.g., Mounjaro, Zepbound).
- The deal is expected to close in Q2 2025, subject to regulatory approvals.
- Lilly previously invested $1.6 billion in a radiopharmaceutical company in 2024.
- The acquisition underscores industry trend toward genetic medicines for cancer.
- Kelonia's technology includes novel delivery systems for gene therapies.
Entities
Institutions
- Eli Lilly
- Kelonia Therapeutics
Sources
- Quartz —